0IGA Stock Overview A life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Emergent BioSolutions Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Emergent BioSolutions Historical stock prices Current Share Price US$9.36 52 Week High US$15.10 52 Week Low US$1.48 Beta 1.6 1 Month Change -5.97% 3 Month Change 2.99% 1 Year Change 289.92% 3 Year Change -80.64% 5 Year Change -82.53% Change since IPO -81.57%
Recent News & Updates
Independent Director recently sold US$273k worth of stock Nov 15
Third quarter 2024 earnings released: EPS: US$2.16 (vs US$5.09 loss in 3Q 2023) Nov 08
Emergent Biosolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa Nov 07
Emergent BioSolutions Inc. Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development, Effective November 18 Nov 05
Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Emergent BioSolutions Inc Oct 25
Emergent BioSolutions Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 23 See more updates
Independent Director recently sold US$273k worth of stock Nov 15
Third quarter 2024 earnings released: EPS: US$2.16 (vs US$5.09 loss in 3Q 2023) Nov 08
Emergent Biosolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa Nov 07
Emergent BioSolutions Inc. Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development, Effective November 18 Nov 05
Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Emergent BioSolutions Inc Oct 25
Emergent BioSolutions Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 23
Emergent BioSolutions’ ACAM2000, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions Aug 30
New minor risk - Profitability Aug 07
Second quarter 2024 earnings released: US$5.38 loss per share (vs US$5.22 loss in 2Q 2023) Aug 07 Emergent BioSolutions Inc. Updates Earnings Guidance for the Full Year of 2024
High number of new directors Aug 02 Emergent BioSolutions Inc. to Report Q2, 2024 Results on Aug 06, 2024 Emergent BioSolutions Inc.(NYSE:EBS) dropped from Russell 3000 Index Emergent BioSolutions Inc. Revises Earnings Guidance for the Year 2024 Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position May 02
Emergent BioSolutions Inc. to Report Q1, 2024 Results on May 01, 2024 Apr 23
New minor risk - Market cap size Apr 18
Emergent BioSolutions Inc., Annual General Meeting, May 23, 2024 Apr 12
High number of new directors Apr 03
Emergent Biosolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility Mar 26
Full year 2023 earnings released: US$14.85 loss per share (vs US$4.22 loss in FY 2022) Mar 07
Emergent BioSolutions Inc. Provides Revenue Guidance for the First Quarter and Earnings Guidance for the Full Year of 2024 Mar 07
Emergent BioSolutions Inc. to Report Q4, 2023 Results on Mar 06, 2024 Mar 01 Emergent BioSolutions Inc. Announces Changes in CEO
Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing Nov 26
Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing Nov 25
Emergent BioSolutions Inc. announced delayed 10-Q filing Nov 11
Emergent BioSolutions Inc. Updates Earnings Guidance for the Year 2023 Nov 10
Emergent BioSolutions Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 20
Emergent Biosolutions Inc. Announces Board Appointments Oct 05
Emergent Biosolutions' Narcan®? Nasal Spray Launches over the Counter Making It Possible for Everyone to Help Save A Life from an Opioid Overdose Emergency Aug 31
Emergent BioSolutions Inc. Announces Demise of Jerome Hauer, Ph.D., Director Aug 17 Emergent BioSolutions Inc. Reports Impairment of Long-Lived Assets for the Second Quarter Ended June 30, 2023 Emergent BioSolutions Inc. Announces Executive Changes
Emergent BioSolutions Inc. to Report Q2, 2023 Results on Aug 08, 2023 Jul 26
Emergent BioSolutions Inc. Receives U.S. FDA Approval of CYFENDUS ( Anthrax Vaccine Adsorbed, Adjuvanted), A Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use Jul 23 Emergent BioSolutions Inc. Announces Resignation of Robert G. Kramer Sr. as President and Member of the Company's Board Emergent BioSolutions Inc.(NYSE:EBS) dropped from Russell 2000 Value-Defensive Index
First quarter 2023 earnings released: US$3.65 loss per share (vs US$0.073 loss in 1Q 2022) May 10
Emergent Biosolutions Inc. Revises Earnings Guidance for the Full Year of 2023 May 10
Full year 2022 earnings released: US$4.47 loss per share (vs US$4.32 profit in FY 2021) Mar 01
Emergent BioSolutions Inc. Reports FDA Advisory Committees’ Unanimous Vote in Favor of NARCAN® (naloxone HCI) Nasal Spray for Over-the-Counter Use Feb 18
Investor sentiment improves as stock rises 19% Feb 17
Emergent BioSolutions Inc. to Report Q4, 2022 Results on Feb 27, 2023 Feb 07
Emergent Biosolutions Inc. Announces Executive Changes Jan 10
Investor sentiment improved over the past week Jan 07
Emergent BioSolutions Inc. Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-The-Counter NARCAN® (Naloxone HCI) Nasal Spray Dec 07
Investor sentiment deteriorated over the past week Nov 18
Now 49% undervalued after recent price drop Nov 10
Emergent BioSolutions Inc. Revises Earnings Guidance for the Year 2022 Nov 09
Emergent BioSolutions Inc. Presents Data from Phase 2 Study Evaluating Safety and Immunogenicity of Chikungunya Vaccine Candidate in Prior Recipients of Other Alphavirus Vaccines Nov 02
Emergent BioSolutions Inc. to Report Q3, 2022 Results on Nov 08, 2022 Oct 19
Emergent BioSolutions Inc. (NYSE:EBS) completed the acquisition of Exclusive Worldwide Rights to Brincidofovir, Including TEMBEXA® from Chimerix, Inc. (NasdaqGM:CMRX) for approximately $370 million. Sep 27
Emergent BioSolutions Inc. Initiates Phase 1 Study Evaluating Lassa Virus Vaccine Candidate Sep 07
Now 22% undervalued after recent price drop Aug 30
Second quarter 2022 earnings released: US$1.13 loss per share (vs US$0.086 profit in 2Q 2021) Aug 02
Now 31% undervalued after recent price drop Aug 02
Emergent BioSolutions Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2022 Aug 02
Emergent Biosolutions Announces Appointment of Sujata Dayal to Board of Directors, Member of the Nominating and Corporate Governance Committee and the Special Committee on Manufacturing and Quality Oversight, Effective July 15, 2022 Jul 07
Emergent BioSolutions Announces U.S. Food and Drug Administration Acceptance of Biologics License Application for AV7909 Anthrax Vaccine Candidate Jun 25
Emergent BioSolutions Inc. Announces Publication of CHIKV VLP Phase 2 Safety and Immunogenicity Data in The Lancet Infectious Diseases Jun 22
Investor sentiment deteriorated over the past week Jun 16
Now 25% undervalued after recent price drop May 24
Investor sentiment improved over the past week May 20 Emergent BioSolutions Inc. (NYSE:EBS) entered into an agreement to acquire Exclusive Worldwide Rights to Brincidofovir, Including TEMBEXA® from Chimerix, Inc. (NasdaqGM:CMRX) for approximately $340 million. May 17
First quarter 2022 earnings released: US$0.073 loss per share (vs US$1.31 profit in 1Q 2021) May 05 Emergent BioSolutions Inc., Annual General Meeting, May 26, 2022 Apr 16
Emergent BioSolutions Inc. to Report Q1, 2022 Results on Apr 28, 2022 Apr 09
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 26
Emergent BioSolutions Inc. Provides Revenue Guidance for First Quarter of 2022 Feb 26 Emergent BioSolutions Inc. Reports Goodwill Impairment for the Fourth Quarter Ended December 31, 2021
Emergent BioSolutions Inc. to Report Q4, 2021 Results on Feb 24, 2022 Feb 22
Emergent BioSolutions Inc. Provides Earnings Guidance for the Full Year 2022 Jan 10
Emergent BioSolutions Inc Announces Initiation of Phase 1 Study Evaluating Its Universal Influenza Vaccine Candidate Dec 17 Shareholder Returns 0IGA GB Biotechs GB Market 7D 12.2% 2.0% 0.4% 1Y 289.9% -24.1% 3.3%
See full shareholder returns
Return vs Industry: 0IGA exceeded the UK Biotechs industry which returned -24.1% over the past year.
Return vs Market: 0IGA exceeded the UK Market which returned 3.3% over the past year.
Price Volatility Is 0IGA's price volatile compared to industry and market? 0IGA volatility 0IGA Average Weekly Movement 13.4% Biotechs Industry Average Movement 10.0% Market Average Movement 4.7% 10% most volatile stocks in GB Market 10.4% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: 0IGA's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0IGA's weekly volatility has decreased from 23% to 13% over the past year, but is still higher than 75% of UK stocks.
About the Company Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector.
Show more Emergent BioSolutions Inc. Fundamentals Summary How do Emergent BioSolutions's earnings and revenue compare to its market cap? 0IGA fundamental statistics Market cap US$518.00m Earnings (TTM ) -US$208.80m Revenue (TTM ) US$1.13b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0IGA income statement (TTM ) Revenue US$1.13b Cost of Revenue US$835.20m Gross Profit US$290.30m Other Expenses US$499.10m Earnings -US$208.80m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -3.85 Gross Margin 25.79% Net Profit Margin -18.55% Debt/Equity Ratio 130.3%
How did 0IGA perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/01 09:42 End of Day Share Price 2024/12/31 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Emergent BioSolutions Inc. is covered by 17 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jasper Hellweg Argus Research Company Robert Wasserman Benchmark Company Louise Chen Cantor Fitzgerald & Co.
Show 14 more analysts 
